Literature DB >> 35072702

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination.

Marton König1, Hilde Marie Torgauten2, The Trung Tran3, Trygve Holmøy4, John Torgils Vaage3, Fridtjof Lund-Johansen3, Gro Owren Nygaard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35072702      PMCID： PMC8787678          DOI： 10.1001/jamaneurol.2021.5109

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN： 2168-6149            Impact factor:   18.302


× No keyword cloud information.
  15 in total

1.  Using proteins to test for COVID antibodies.

Authors:  Helen Santoro
Journal:  Nature       Date:  2022-10       Impact factor: 69.504

Review 2.  SARS-CoV-2 infection in multiple sclerosis patients: interaction with treatments, adjuvant therapies, and vaccines against COVID-19.

Authors:  Ana Muñoz-Jurado; Begoña M Escribano; Eduardo Agüera; Javier Caballero-Villarraso; Alberto Galván; Isaac Túnez
Journal:  J Neurol       Date:  2022-07-05       Impact factor: 6.682

3.  Third COVID-19 jab benefits people with MS.

Authors:  Sarah Lemprière
Journal:  Nat Rev Neurol       Date:  2022-03       Impact factor: 44.711

4.  Seroconversion following COVID-19 vaccination: Can we optimize protective response in CD20-treated individuals?

Authors:  David Baker; Amy MacDougall; Angray S Kang; Klaus Schmierer; Gavin Giovannoni; Ruth Dobson
Journal:  Clin Exp Immunol       Date:  2021-11-18       Impact factor: 5.732

5.  Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine.

Authors:  Livnat Brill; Ariel Rechtman; Alla Shifrin; Ayal Rozenberg; Svetlana Afanasiev; Omri Zveik; Nitzan Haham; Neta Levin; Adi Vaknin-Dembinsky
Journal:  Mult Scler Relat Disord       Date:  2022-05-10       Impact factor: 4.808

Review 6.  Multiple Sclerosis Management During the COVID-19 Pandemic.

Authors:  Chris Hollen; Jacqueline Bernard
Journal:  Curr Neurol Neurosci Rep       Date:  2022-06-10       Impact factor: 6.030

Review 7.  Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.

Authors:  Maryam Golshani; Jiří Hrdý
Journal:  Vaccines (Basel)       Date:  2022-02-11

Review 8.  Vaccination and immunotherapies in neuroimmunological diseases.

Authors:  Alexander Winkelmann; Micha Loebermann; Michael Barnett; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2022-04-06       Impact factor: 44.711

Review 9.  Safety, immunogenicity, efficacy, and acceptability of COVID-19 vaccination in people with multiple sclerosis: a narrative review.

Authors:  Fioravante Capone; Mariagrazia Rossi; Alessandro Cruciani; Francesco Motolese; Fabio Pilato; Vincenzo Di Lazzaro
Journal:  Neural Regen Res       Date:  2023-02       Impact factor: 6.058

10.  SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod.

Authors:  Julian Braun; Florent Fauchere; Kanika Vanshylla; Friedemann Paul; Judith Bellmann-Strobl; Andreas Thiel; Claudia Giesecke-Thiel; Lil Meyer-Arndt; Lucie Loyal; Larissa Henze; Beate Kruse; Manuela Dingeldey; Karsten Jürchott; Maike Mangold; Ardit Maraj; Andre Braginets; Chotima Böttcher; Andreas Nitsche; Kathrin de la Rosa; Christoph Ratswohl; Birgit Sawitzki; Pavlo Holenya; Ulf Reimer; Leif E Sander; Florian Klein
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-07-14       Impact factor: 13.654
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.